PD-1 Inhibitor

26 registered clinical trials studyying PD-1 Inhibitor — 18 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophag NCT07531979	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Not Yet Recruiting	Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS NCT07394192	Peking University Cancer Hospital & Institute	Phase 2
Recruiting	Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer NCT07233252	Tianjin Medical University Second Hospital	Phase 2
Recruiting	LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study NCT07312422	Zhejiang Provincial People's Hospital	Phase 1 / Phase 2
Not Yet Recruiting	Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-ass NCT07133776	The Affiliated Hospital of Xuzhou Medical University	Phase 1 / Phase 2
Not Yet Recruiting	Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated L NCT07133763	The Affiliated Hospital of Xuzhou Medical University	Phase 1 / Phase 2
Recruiting	Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC NCT07126119	Tianjin Medical University Second Hospital	Phase 2
Recruiting	Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer NCT07125547	Tianjin Medical University Second Hospital	Phase 2
Recruiting	Neoadjuvant Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer NCT06903858	Sun Yat-sen University	Phase 2
Recruiting	Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Meta NCT06809530	Guangzhou Medical University	Phase 1 / Phase 2
Not Yet Recruiting	Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer NCT06871527	Sixth Affiliated Hospital, Sun Yat-sen University	Phase 1 / Phase 2
Recruiting	Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC NCT06811844	The First Affiliated Hospital of Xiamen University	Phase 2
Active Not Recruiting	Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer NCT06865521	West China Hospital	N/A
Recruiting	Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lun NCT06431685	Sichuan University	Phase 1
Unknown	Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma NCT05913661	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2
Unknown	Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma NCT05675033	Fujian Cancer Hospital	Phase 2
Recruiting	Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell NCT06006650	Tang-Du Hospital	Phase 2
Recruiting	Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody NCT05392413	Nanfang Hospital, Southern Medical University	—
Active Not Recruiting	PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma NCT05340270	Guangxi Medical University	Phase 2
Unknown	Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle I NCT05401279	RenJi Hospital	Phase 2
Recruiting	Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcin NCT05290194	Fifth Affiliated Hospital, Sun Yat-Sen University	Phase 2
Unknown	PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure NCT05222035	Sun Yat-sen University	Phase 2
Unknown	G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma NCT05222009	Sun Yat-sen University	Phase 1
Recruiting	Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC. NCT05615142	Sichuan University	Phase 1
Unknown	Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma NCT05048017	Peking Union Medical College Hospital	Phase 2
Recruiting	HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma NCT06333561	Sun Yat-sen University	—